In order to establish tumor signaling pathway effects of the FAK+MEK inhibitor combination, beyond direct targets such as p-ERK, we profiled cell lines either resistant or sensitive to both monotherapies (E13 and E57 cells, respectively) by RPPA (127 verified antibodies, relating to common anti-cancer and adhesion signaling pathways), after treatment with either DMSO 0.1%, trametinib (100 nM), VS4718 (300 nM), or in combination for 24 h. The gene discussed is PTK2; the disease is neoplasm.